Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Understanding metastasis mixed-treatment responses through genomic analyses.
NPJ Breast Cancer
January 2025
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Early-stage and metastatic breast cancers (MBC) can exhibit genomic heterogeneity, even within the same individual. Response to therapy in metastatic breast cancer patients with multiple metastases can also be heterogeneous, with different degrees of responsiveness to the same drug(s) across metastatic sites, termed "mixed response," within the same patient. Whether this treatment response variability is influenced by factors such as intrinsic tumor characteristics of metastatic lesions and/or the microenvironment is unknown.
View Article and Find Full Text PDFDiagnostic Performance of the Modified Lung-RADS in a Tuberculosis-endemic Country: The Korean National Lung Cancer Screening Program.
Chest
January 2025
Division of Cancer Early Detection, National Cancer Control Institute, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea. Electronic address:
Background: In 2019, Korea initiated the world's first national low-dose computed tomography (CT) lung cancer screening (LCS) program, adapting the Lung CT Screening Reporting and Data System (Lung-RADS) to counteract the high false-positive rates driven by prevalent tuberculosis.
Research Question: Does the modified Lung-RADS enhance screening specificity while maintaining sensitivity?
Study Design And Methods: This nationwide, retrospective, cohort study included high-risk current smokers aged 54 to 74 with at least 30 pack-years, participating in the national LCS program from 2019 to 2020. The modified Lung-RADS 1.
Early release of circulating tumor cells after transarterial chemoembolization hinders therapeutic response in patients with hepatocellular carcinoma.
J Transl Med
January 2025
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain.
Background: Transarterial chemoembolization (TACE) is the first-line therapeutic option for patients with intermediate-stage hepatocellular carcinoma (HCC). Tumor neovascularization allows tumor growth and may facilitate the release of circulating tumor cells (CTCs) to the bloodstream after TACE. We investigated the relationship between early release of CTCs and radiological response after TACE.
View Article and Find Full Text PDFA Phase I/IIa Clinical Trial to Evaluate Safety and Adrenal Uptake of Para-Chloro-2-[F]Fluoroethyletomidate in Healthy Volunteers and Patients with Primary Aldosteronism.
J Nucl Med
January 2025
Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom;
Primary aldosteronism (PA) is a common, potentially reversible, cause of hypertension. Distinguishing unilateral from bilateral PA is critical when deciding who should be offered surgery (unilateral adrenalectomy). Recent studies have shown that PET/CT with [C]metomidate can accurately identify unilateral PA, with localization of the causative aldosterone-producing adenoma (APA).
View Article and Find Full Text PDFReview of Endosaccular Flow Disrupters for Wide-Neck Aneurysm Treatment.
Cardiol Rev
January 2025
From the Department of Neurological Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
Endosaccular flow disruption has emerged as a transformative approach for treating wide-neck intracranial aneurysms, which are characterized by neck diameters exceeding 4 millimeters or dome-to-neck ratios below 2. This review examines the technical specifications and clinical outcomes of major endosaccular devices, including the Woven EndoBridge (WEB) device, the Artisse embolization device, the Medina embolization device, the neck bridging device for bifurcation aneurysms, the polycarbonate urethane membrane-assisted device, the Galaxy saccular endovascular aneurysm lattice, and the Contour Neurovascular System. Analysis of pivotal trials reveals varying degrees of efficacy and safety across platforms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!